Smith M I, Wertheimer A I
J Health Polit Policy Law. 1979 Summer;4(2):155-75. doi: 10.1215/03616878-4-2-155.
In 1973 the federal government moved to limit drug reimbursement to providers in federally sponsored or supported programs, to the lowest cost at which the drug is generally and consistently available unless a difference in therapeutic effect can be demonstrated between the brand name and generic drug. This paper examines the political evolution and rationale for this program and explores the issues surrounding the ongoing controversy regarding publicly financed programs offering drug benefits. The authors speculate that the government's first attempt to control prices of pharmaceuticals, prior to enactment of some form of national health insurance, if successful, will call forth pharmaceutical industry strategies which could negate program benefits.
1973年，联邦政府采取行动，将联邦政府资助或支持项目中向供应商支付的药品报销费用限制在该药品普遍且持续可得的最低成本，除非能证明品牌药和仿制药在治疗效果上存在差异。本文考察了该项目的政治演变及其背后的原理，并探讨了围绕公共资助的药品福利项目持续争议的相关问题。作者推测，在某种形式的国家医疗保险颁布之前，政府首次控制药品价格的尝试若取得成功，可能会引发制药行业的应对策略，从而抵消该项目的益处。
